| Disease | demyelinating disease |
| Phenotype | C0021390|inflammatory bowel disease |
| Sentences | 1 |
| PubMedID- 25348720 | Conclusion: anti-tnfalpha biologics do not appear to impact the risk of developing clinical idiopathic inflammatory demyelinating disease in patients with inflammatory bowel disease. |
Page: 1